With a frequent mutation rate in AML of about 20–30% occurring with an intermediate prognosis and high relapse rates, the FMS-like tyrosine kinase 3 (FLT3) gene became a popular target within the past decade [3,7]. This evidence concerns the gene FLT3 and acute myeloid leukemia.